文摘
The development of a short, safe and enantioselective route forthe preparation of (R)-aminoglutethimide is described. Theprocess was designed for economic large-scale manufacture ofthe bulk drug substance to acceptable quality standards, toallow clinical evaluation of the single enantiomer over theexisting racemate. (R)-Aminoglutethimide was prepared from1-chloro-4-nitrobenzene using a six-stage synthetic sequence,via chemoresolution of key intermediate racemic 4-cyano-4-(4-nitrophenyl)hexanoic acid using (-)-cinchonidine. The processallowed for preparation of several kilograms of the precursor(R)-nitroglutethimide, to cGMP at pilot-plant scale, along withdemonstration of the final hydrogenation step to (R)-aminoglutethimide in the laboratory. This route avoids the problemsof hazardous nitration technology, and therefore regio-isomercontamination of the product, associated with other procedures.The resolution chemistry described represents an improvementon literature procedures. Optimisation of the asymmetricMichael addition offers an attractive alternative approach.